The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
OMX-0407: A novel spectrum-selective small molecule kinase inhibitor in advanced/metastatic solid tumors.
 
Valentina Boni
Employment - Next Oncology; Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - 1TRIALSP
Honoraria - Amunix; EMD Serono/Merck; Guidepoint Global; IDEAYA Biosciences; Janssen Oncology; Loxo; MSD Oncology; Puma Biotechnology
Consulting or Advisory Role - EMD Serono/Merck; Guidepoint Global; Janssen Research & Development; Lilly; Lilly; Nanobiotix; Novartis; OncoArt
Speakers' Bureau - Lilly; MSD; Solti; TACTICS; TACTICS
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; European Organisation for Research and Treatment of Cancer (EORTC); Merus NV; Novartis; PharmaMar; Sanofi; START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Amunix; Anaveon; AstraZeneca/MedImmune; Bristol-Myers Squibb; Chugai Pharma; Diaccurate; Elevation Oncology; Ellipses Pharma; Genmab; Janssen-Cilag; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; Roche/Genentech; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences
 
Omar Saavedra
No Relationships to Disclose
 
Jean-Pascal Machiels
Consulting or Advisory Role - ALX Oncology; ANAVEON (Inst); Astellas Pharma (Inst); AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CUE Biopharma; CureVac (Inst); eTHERNA; F-star; Genmab (Inst); GlaxoSmithKline (Inst); Incyte; Innate Pharma; IPSEN (Inst); ITeos Therapeutics; Janssen; Merck Serono; Merus (Inst); MSD Oncology (Inst); NEKTAR; Novartis; Pfizer; Roche; Seagen (Inst); Seagen (Inst)
Research Funding - Bayer; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Gilead Sciences; Merck Serono (Inst); MSD; Pfizer
Other Relationship - PsiOxus Therapeutics
 
Juan Martin-Liberal
Consulting or Advisory Role - Bristol-Myers Squibb; Highlight Therapeutics; Ipsen; Novartis; Pierre Fabre; Roche; Sanofi; Trialing Health
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche
 
Nadia Hindi
Honoraria - Deciphera; PharmaMar
Consulting or Advisory Role - Deciphera; PharmaMar
Research Funding - Abbisko Therapeutics (Inst); Adaptimmune (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Pfizer (Inst); CEBIOTEX (Inst); Cogent Biosciences (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim Spain; Deciphera; PharmaMar
 
Irene Carrasco-Garcia
Honoraria - PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Cogent Medicine (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Javier Martínez-Trufero
Consulting or Advisory Role - Boehringer Ingelheim Spain; Deciphera; Eisai; GlaxoSmithKline; PharmaMar
Research Funding - Ayala Pharmaceuticals (Inst); BionTech (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Kariopharm Therapeutics (Inst); Lilly (Inst); PharmaMar (Inst); Syneos Health (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Merck; PharmaMar; PharmaMar; Roche
 
Ilona-Petra Maser
Employment - iOmx Therapeutics AG
Stock and Other Ownership Interests - iOmx Therapeutics AG
Patents, Royalties, Other Intellectual Property - Patents related to OMX-0407 a Tyrosine kinase inhibitor for use in solid cancers developed by iOmx Therapeutics AG (Inst)
 
Marisa Stebegg-Wagner
Employment - iOmx Therapeutics AG
Stock and Other Ownership Interests - iOmx Therapeutics AG
Patents, Royalties, Other Intellectual Property - 4 patents with Sanofi
 
Hannes Loferer
Employment - iOmx Therapeutics AG
Leadership - iOmx Therapeutics AG
Stock and Other Ownership Interests - iOmx Therapeutics AG
Travel, Accommodations, Expenses - iOmx Therapeutics AG
 
Tiantom Jarutat
Employment - iOmx Therapeutics
Leadership - iOmx Therapeutics
Stock and Other Ownership Interests - iOmx Therapeutics
Research Funding - iOmx Therapeutics
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Claudia Valverde Morales
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Deciphera; PharmaMar; Philogen
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst)
Travel, Accommodations, Expenses - PharmaMar